AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33893705
Drug: Control (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (inhaled sevoflurane anaesthesia)
Trial: 36317958
Drug: Cangrelor (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cangrelor (bolus and infusion for 2 hours)
Trial: 33864607
Drug: Testosterone treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone treatment, n = 6
Trial: 33864607
Drug: Placebo treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment, n = 8
Trial: 34068824
Drug: Average amount
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average amount of alcohol consumed weekly (in frequent drinkers with obesity)
Trial: 34366153
Drug: Henagliflozin 10
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Henagliflozin 10 mg in the fasted condition
Trial: 34366153
Drug: Henagliflozin 10
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Henagliflozin 10 mg in the fed condition
Trial: 34366153
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal prior to henagliflozin administration
Trial: 34212234
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (0.1% triamcinolone acetonide)
Trial: 33846016
Drug: Increasing number
RxNorm normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing number of statin prescriptions
Trial: 34114493
Drug: Cellular medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellular medicine trials (including stem cell therapy) for COVID-19
Trial: 34114493
Drug: COVID-19 cellular
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 cellular medicine trials
Trial: 35775704
Drug: Conventional photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional photodynamic therapy (c-PDT)
Trial: 35775704
Drug: Daylight photodynamic
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daylight photodynamic therapy (dl-PDT)
Trial: 32469304
Drug: L-carnitine and
RxNorm normalized name: Fat Burner with Chromium Picolinate, L-Carnitine and Iron Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine and piracetam (10 mL of a solution containing L-carnitine 100 mg/mL + piracetam 80 mg/mL)
Trial: 32469304
Drug: L-carnitine and
RxNorm normalized name: Fat Burner with Chromium Picolinate, L-Carnitine and Iron Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine and piracetam
Trial: 35386730
Drug: Dialectical Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behaviour Therapy for PTSD (DBT-PTSD)
Trial: 33109679
Drug: Oral hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydroxyurea 10-20 mg/kg daily for 6 months
Trial: 35361632
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of methylprednisolone intravenously for three consecutive days
Trial: 34605100
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine administration
Trial: 36424125
Drug: Prophylactic surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic surfactant nebulisation (SN) at 200 mg/kg (poractant alfa)
Trial: 32974844
Drug: κ‐selenocarrageenan supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: κ‐selenocarrageenan supplementation at selenium (Se) levels of 2.0 μg/g
Trial: 32740286
Drug: Sceletium tortuosum
RxNorm normalized name: Mesembryanthemum tortuosum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sceletium tortuosum (ST) extract (25-mg) supplementation
Trial: 32306803
Drug: Low-dose multi-strain
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose multi-strain probiotic (5 billion CFU)
Trial: 32306803
Drug: High-dose multi-strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose multi-strain probiotic (25 billion CFU)
Trial: 33629921
Drug: QX003S (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QX003S (8 mg/kg)
Trial: 32691938
Drug: Sequencing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequencing treatment of oral oxybutynin chloride after BTX‐A injections
Trial: 32691938
Drug: Oral oxybutynin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxybutynin chloride in monotherapy
Trial: 33989683
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (observation)
Trial: 32348007
Drug: Amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin plus Berberine (BA group)
Trial: 35766242
Drug: Sensory integration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory integration therapy delivered over 26 weeks
Trial: 35766242
Drug: Sensory integration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory integration therapy
Trial: 33190575
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of cocoa-rich chocolate (99%) daily for 6 months
Trial: 32840418
Drug: Rucaparib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib (600 mg twice per day)
Trial: 33899689
Drug: CALAS (Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CALAS (Capsule of alkaloids from Alstonia scholaris leaves)
Trial: 33369791
Drug: Procnew15s (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procnew15s (single inhalation of CO bolus with 15s breath hold)
Trial: 33369791
Drug: Procnew30s (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procnew30s (single inhalation of CO bolus with 30s breath hold)
Trial: 32868637
Drug: Resveratrol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 2.5 g + 0 mg piperine
Trial: 32868637
Drug: Resveratrol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 2.5 g + 5 mg piperine
Trial: 32868637
Drug: Resveratrol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 2.5 g + 25 mg piperine
Trial: 36384321
Drug: Perineural hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perineural hypertonic saline injection (5%)
Trial: 36384321
Drug: Foot acupoints
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot acupoints hypertonic saline injection (5%)
Trial: 34553296
Drug: Lapatinib+capecitabine (L+C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib+capecitabine (L+C)
Trial: 35331536
Drug: High flavonoid
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavonoid cocoa (10.79 mg/g)
Trial: 35331536
Drug: Low flavonoid
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flavonoid cocoa (1.02 mg/g)
Trial: 36012924
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (STAG)
Trial: 33503289
Drug: ALPN-101 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALPN-101 (3 mg/kg SC)
Trial: 33503289
Drug: ALPN-101 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALPN-101 (10 mg/kg IV)
Trial: 33503289
Drug: ALPN-101 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALPN-101 (1 mg/kg IV, 4 weekly doses)
Trial: 33503289
Drug: ALPN-101 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALPN-101 (various doses)
Trial: 34980505
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (CP) with high-titre neutralizing anti-SARS-CoV-2 antibodies (CCP), administered in a maximum of three therapeutic fractions (TFs) over 3-5 days, with a neutralizing antibody titre of = 1:160 or = 1:80 if unavailable.
Trial: 34980505
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (CP) with high-titre neutralizing anti-SARS-CoV-2 antibodies (CCP)
Trial: 32811378
Drug: Control (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (usual care physical therapy: 1 hour, 5 days/week)
Trial: 34617309
Drug: Daily prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily prednisolone (0.75 mg/kg/day)
Trial: 34617309
Drug: Intermittent prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent prednisolone (0.75 mg/kg/day for first 10 days of every month)
Trial: 32814747
Drug: HK‐LS HS‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HK‐LS HS‐1 supplement
Trial: 35169280
Drug: Febuxostat treatment
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat treatment group
Trial: 35793182
Drug: PKP +
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PKP + LAI (lidocaine + triamcinolone acetonide injections)
Trial: 34571091
Drug: TPF induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF induction chemotherapy (75 mg/m2 cisplatin and 75 mg/m2 docetaxel on day 1 and 750 mg/m2 fluorouracil from the first to the fifth day)
Trial: 34491123
Drug: Zanubrutinib (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanubrutinib (320 mg once daily or 160 mg twice daily)
Trial: 33617042
Drug: CJM112 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CJM112 15 mg, 50 mg, and 150 mg subcutaneous (s.c.)
Trial: 33617042
Drug: CJM112 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CJM112 450 mg subcutaneous (s.c.)
Trial: 33617042
Drug: CJM112 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CJM112 150 mg high frequency
Trial: 33253089
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg subcutaneous (s.c.)
Trial: 34936273
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aerosol (125 μg per inhalation, twice a day)
Trial: 32816578
Drug: L-Carnitine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitine (1000 mg/day)
Trial: 32389396
Drug: Analgesics provided
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics provided
Trial: 32214296
Drug: Hyalase +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyalase + 10 mL saline solution injection
Trial: 32214296
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL saline solution only
Trial: 33267591
Drug: Almagate (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almagate (1.5 g)
Trial: 35773711
Drug: Phasic muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phasic muscle therapy protocol using the StimaWELL 120MTRS system
Trial: 35773711
Drug: Combined muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined muscle therapy protocol (phasic + tonic) using the StimaWELL 120MTRS system
Trial: 33200808
Drug: PHP (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHP (in subgroup analysis excluding antithrombotic agents)
Trial: 33200808
Drug: Control (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (in subgroup analysis excluding antithrombotic agents)
Trial: 32078948
Drug: Peginterferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon beta‐1a 125 mcg every 2 weeks
Trial: 33691647
Drug: Therap-i module
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therap-i module integrated into treatment as usual (TAU) for depression
Trial: 33104761
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) and psychopharmacology within a collaborative care model
Trial: 32448335
Drug: Apatinib mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib mesylate (500 mg, once daily) combined with vinorelbine (40 mg, thrice a week)
Trial: 32448335
Drug: Vinorelbine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine alone (40 mg, thrice a week)
Trial: 33515781
Drug: TAKE IT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAKE IT intervention (multifaceted medication adherence monitoring strategy)
Trial: 34022839
Drug: Food literacy
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food literacy constructs including nutrition knowledge, food preparation and cooking skills, self-efficacy and behaviours, food waste knowledge and behaviours, and food production knowledge.
Trial: 35925872
Drug: Individualized nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized nutritional interventions with normoproteic diets (1.0 g/kg) after 60 days of KTx
Trial: 35595091
Drug: Empagliflozin 10mg
RxNorm normalized name: EMPAGLIFLOZIN 10MG TAB
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 10mg daily in addition to standard care
Trial: 32668114
Drug: Accelerated strategy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated strategy of renal-replacement therapy (initiated within 12 hours)
Trial: 32668114
Drug: Standard strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard strategy of renal-replacement therapy (initiated after 72 hours or conventional indications)
Trial: 32668114
Drug: Accelerated strategy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated strategy of renal-replacement therapy
Trial: 32668114
Drug: Standard strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard strategy of renal-replacement therapy
Trial: 36464237
Drug: 2 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Hz electroacupuncture treatment
Trial: 36464237
Drug: 20/100 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/100 Hz electroacupuncture treatment
Trial: 34134645
Drug: Chronic anticoagulation
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic anticoagulation therapy
Trial: 34134645
Drug: No anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulation therapy (Control)
Trial: 33354803
Drug: Improvac® (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvac® (two doses, 28 days apart)
Trial: 32456572
Drug: Hemp Oil
RxNorm normalized name: HEMP OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemp Oil Extract (60 mg/d, 15 mg hemp-derived CBD)
Trial: 33620619
Drug: Adjunctive posterior
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive posterior wall isolation
Trial: 36459243
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA vaccine
Trial: 34836429
Drug: HAPIFED (integrates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAPIFED (integrates cognitive behavioural therapy with body weight loss therapy)
Trial: 34836429
Drug: CBT‐E (cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT‐E (cognitive behavioural therapy with extended sessions alone)
Trial: 33356033
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors in addition to baseline treatment (Group A)
Trial: 33356033
Drug: Baseline treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline treatment or other medications as needed (Group B)
Trial: 36179736
Drug: Oral fexinidazole
RxNorm normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fexinidazole
Trial: 34969771
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg BMS-986278
Trial: 34969771
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg BMS-986278
Trial: 32205595
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment without a preestablished routine
Trial: 33845761
Drug: Dexmedetomidine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.6 µg/kg/h)
Trial: 34981180
Drug: Topiramate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (200 mg/day for 5 weeks)
Trial: 32007328
Drug: Administration, workload,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration, workload, relationships with colleagues, work itself, remuneration and benefits
Trial: 33829803
Drug: FORNET (Narrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FORNET (Narrative Exposure Therapy for Forensic Offender Rehabilitation)
Trial: 33158948
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance index (IRI)
Trial: 34730461
Drug: Dried egg
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried egg white protein supplementation (20 g protein daily)
Trial: 34730461
Drug: Isocaloric maltodextrin
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric maltodextrin supplement
Trial: 35356054
Drug: 30-minutes of
RxNorm normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-minutes of daily morning bright white light (BWL)
Trial: 34713539
Drug: Subantibiotic dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily (SDD40)
Trial: 33885773
Drug: Default dispense
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Default dispense quantity of 10 tablets
Trial: 34325109
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2 followed by trabectedin 1.1 mg/m2 as a 3‐h infusion on day 1 and pegfilgrastim on day 2, every 3 weeks, up to six cycles
Trial: 34674896
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser therapy (Ga-As super pulsed laser therapy)
Trial: 34674896
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser therapy (inactive laser)
Trial: 34064427
Drug: Fascia Iliaca
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia Iliaca Compartment Block (FICB) with 0.375% ropivacaine, nonopioid analgesics (paracetamol, metamizole, pregabalin), and oxycodone as rescue analgesia
Trial: 34064427
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous analgesia with FICB
Trial: 36619342
Drug: Big patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Big patch (30,000 IU cholecalciferol)
Trial: 36619342
Drug: Small patch
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small patch (30,000 IU cholecalciferol)
Trial: 36619342
Drug: Both patches
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both patches (30,000 IU cholecalciferol)
Trial: 32308680
Drug: Insulin administration
RxNorm normalized name: insulin administration supplies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin administration
Trial: 34635374
Drug: Biological contamination
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological contamination
Trial: 35174663
Drug: Leucine 2.5
RxNorm normalized name: isoleucine 2.52 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucine 2.5 g thrice daily
Trial: 35174663
Drug: Meta-analysis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meta-analysis of ACE inhibitors/ARBs
Trial: 32594675
Drug: Triple chronotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple chronotherapy (combined total sleep deprivation, light therapy, and sleep phase advance) add-on to standard pharmacological treatment